A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆

Authors:

Abstract
No abstract available
Funding Information
  • Pfizer
  • Meso Scale Diagnostics
  • Genentech
  • Merck KGaA
  • GlaxoSmithKline
  • Exelixis
  • Merck
  • Les Laboratories Pierre Fabre
  • Bristol-Myers Squibb
  • Roche
  • Novartis

This publication has 28 references indexed in Scilit: